IDEC Pharmaceuticals

IDEC Pharmaceuticals focuses on developing therapies for neurodegenerative, hematologic, and autoimmune diseases, with a particular emphasis on cancer treatments. Founded in 1986 by a group of researchers and entrepreneurs, including Ivor Royston and Howard Birndorf, the company originally aimed to develop and commercialize monoclonal antibodies. IDEC Pharmaceuticals gained recognition for its innovative approaches to treating conditions such as non-Hodgkin's lymphoma. In 2003, the company merged with Biogen, further expanding its capabilities in the biopharmaceutical industry.